Introduction
Methods
Patients
Colony-forming unit assay and circulating eEPCs
Biochemical and hematological tests
Pulse wave analysis and vascular augmentation index (AIX)
Statistical analysis
Results
p value | |
---|---|
CFU-ECs | |
Ps < vs. ≥ mean DOD | 0.15 |
PsA < vs. ≥ mean DOD | 0.72 |
Ps < vs. ≥ mean PASI | 0.94 |
PsA < vs. ≥ mean VAS | 0.84 |
Ps biological− vs. biological+ | 0.94 |
PsA biological− vs. biological+ | 0.16 |
Ps < vs. ≥ mean CRP | 0.53 |
PsA < vs. ≥ mean CRP | 0.87 |
CD133+/KDR+ cells (%) | |
Ps < vs. ≥ mean DOD | 0.23 |
PsA < vs. ≥ mean DOD | 0.65 |
Ps < vs. ≥ mean PASI | 0.66 |
PsA < vs. ≥ mean VAS | 0.11 |
Ps biological− vs. biological+ | 0.68 |
PsA biological− vs. biological+ | 0.58 |
Ps < vs. ≥ mean CRP | 0.65 |
PsA < vs. ≥ mean CRP | 0.24 |
PWV (m/s) | |
Ps < vs. ≥ mean DOD | 0.34 |
PsA < vs. ≥ mean DOD | 0.70 |
Ps < vs. ≥ mean PASI | 0.83 |
PsA < vs. ≥ mean VAS | 0.59 |
Ps biological− vs. biological+ | 0.51 |
PsA biological− vs. biological+ | 0.42 |
Ps < vs. ≥ mean CRP | 0.34 |
PsA < vs. ≥ mean CRP | 0.07 |
AIX | |
Ps < vs. ≥ mean DOD | 0.2 |
PsA < vs. ≥ mean DOD | 0.74 |
Ps < vs. ≥ mean PASI | 0.63 |
PsA < vs. ≥ mean VAS | 0.29 |
Ps biological− vs. biological+ | 0.09 |
PsA biological− vs. biological+ | 0.40 |
Ps < vs. ≥ mean CRP | 0.43 |
PsA < vs. ≥ mean CRP | 0.91 |
Subjects
Ps | PsA | |
---|---|---|
Sex | f: 13; m: 17 | f: 15; m: 16 |
Age (years as mean ± SEM) | 49.0 ± 2.8 | 47.7 ± 2.0 |
Duration of disease (DOD—mean years ± SEM) | 18.3 ± 2.7 | 13.0 ± 2.4 |
CRP (mg/dl—mean ± SEM) | 3.7 ± 0.7 | 5.1 ± 1.4 |
PASI | 10.2 ± 2.0 | – |
Pain index (VAS in mm) | – | 47.1 ± 4.4 |
Treatment with Biological (%) | 33.3 | 45.1 |
Arterial hypertension (%) | 40.0 | 41.9 |
Smoking (%) | 70.0 | 64.5 |
Statin treatment (%) | 3.3 | 19.3 |
Diabetes mellitus (%) | 10.0 | 16.1 |
PWV (m/s—mean ± SEM) | 8.0 ± 0.4 | 7.4 ± 0.3 |
AIX (%—mean ± SEM) | 21.6 ± 2.8 | 19.8 ± 2.6 |
CFU-ECs (mean ± SEM) | 22.1 ± 3.3 | 24.2 ± 3.1 |
CD133+/KDR+ cells (%—mean ± SEM) | 8.0 ± 0.6 | 9.5 ± 1.5 |